Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medipal HoldingsMAHLY 82 EBIT per Share is $2.61 as of Mar. 2026. GuruFocus rates MAHLY with a GF Score™ of 82/100 and a GF Value™ of $16.38 (Fairly Valued). The stock has 1 warning sign investors should review. Among 105 Medical Distribution companies, Medipal Holdings ranks better than 51.43% on this metric.
Medipal Holdings's EBIT per Share for the
three
months ended in Mar. 2026 was $0.47.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was $2.61.
During the past 12 months, the average EBIT per Share Growth Rate of Medipal Holdings was -3.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 4.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 8.40% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 3.50% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Medipal Holdings's EBIT per Share or its related term are showing as below:
MAHLY'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -27.1 Med: 4.1 Max: 17.7
Current: 4.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Medipal Holdings was 17.70% per year. The lowest was -27.10% per year. And the median was 4.10% per year.
MAHLY's 3-Year EBIT Growth Rate is ranked better than 51.43% of 105
companies
in the Medical Distribution industry
Industry Median: 4.2
vs MAHLY: 4.60
Medipal Holdings (OTCPK:MAHLY) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Medipal Holdings EBIT per Share Related Terms
Medipal Holdings EBIT per Share Historical Data
* Premium members only.
The historical data trend for Medipal Holdings's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $2.61
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medipal Holdings (MAHLY) has a EBIT per Share of $2.61 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medipal Holdings and its competitors. According to the industry distribution chart, Medipal Holdings ranks #51 out of 105 companies in the Medical Distribution industry, placing it in the top 48.6%.
Is Medipal Holdings' EBIT per Share too high?
Medipal Holdings' current EBIT per Share is $2.61. The Medical Distribution industry median EBIT per Share is 4.20. Medipal Holdings' value of $2.61 is 37.9% below this industry median. Based on the distribution chart, Medipal Holdings ranks #51 out of 105 companies in the Medical Distribution industry, which is above the industry midpoint. Overall, Medipal Holdings has a GF Score™ of 82/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Medipal Holdings' EBIT per Share compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Medipal Holdings ranks #51 out of 105 companies for EBIT per Share. This puts Medipal Holdings in the upper half of its industry. The industry median EBIT per Share is 4.20. Medipal Holdings' value of $2.61 is 37.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.20, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medipal Holdings's current EBIT per Share of $2.61 is 37.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Medipal Holdings and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medipal Holdings's current EBIT per Share is $2.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medipal Holdings stock overvalued right now?
Based on GuruFocus' analysis, Medipal Holdings (MAHLY) is currently considered Fairly Valued. The stock's GF Value™ is $16.38, compared to a current price of $17.99 — trading 9.8% above its estimated fair value. The current EBIT per Share is $2.61 and 37.9% below the Medical Distribution industry median of 4.20. Medipal Holdings' overall GF Score™ is 82/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Medipal Holdings (MAHLY), the current EBIT per Share is $2.61 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medipal Holdings (MAHLY) Overvalued in 2026?
Based on GuruFocus' analysis, Medipal Holdings stock appears to be overvalued.
The current stock price of $17.99 is trading 9.8% above its estimated GF Value™ of $16.38.
GuruFocus considers Medipal Holdings to be Fairly Valued.
Key valuation signals for MAHLY:
EBIT per Share: $2.61
GF Value™: $16.38 vs. price of $17.99 (9.8% above fair value)
Industry Position: 37.9% below the Medical Distribution median (#51 of 105)
No single metric tells the full story. See the MAHLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medipal Holdings Corp is engaged in the wholesale distribution of pharmaceuticals, cosmetics, daily necessities, and related products. The company operates through three reportable segments: Wholesale business of medical drugs; Cosmetics, Daily Necessities and OTC Pharmaceuticals Wholesale Business; and Wholesale of animal medicines and food processing ingredients. The Wholesale business of medical drugs segment targets hospitals, clinics, and dispensing pharmacies; the Cosmetics and OTC segment serves drug stores, home centers, convenience stores, and supermarkets; while the Wholesale of animal medicines and food processing ingredients segment supplies veterinary clinics, livestock and fisheries businesses, and food manufacturers.
82GF Score
Get the complete analysis for MAHLY
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MAHLY has been successfully added to your 
